Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
Zeinab Awada,1 Natasha Hameed,2 Asaff Harel1,2 1Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA; 2Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Lon...
Saved in:
| Main Authors: | Awada Z, Hameed N, Harel A |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/profile-of-ofatumumab-in-the-treatment-of-multiple-sclerosis-design-de-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura
by: Yuki Yokota, et al.
Published: (2025-03-01) -
The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01) -
Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis
by: Wioletta Katarzyna Żukowicz-Wyrwa, et al.
Published: (2025-08-01) -
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01) -
Role of Diet and Supplementation with Omega-3 Polyunsaturated Fatty Acids for Managing Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis
by: Nicholas Shepherd, et al.
Published: (2022-11-01)